The Business Research Company’s report on the Clinical Biomarkers Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the clinical biomarkers market’s growth in recent years?
High cancer prevalence is expected to propel the growth of the clinical biomarker market going forward. Cancer is a term used to describe a group of disorders in which abnormal cells grow and divide uncontrollably, with the potential to invade and harm healthy bodily tissue. Clinical biomarkers play a crucial role in cancer prevention by aiding in early detection, risk assessment, and monitoring of individuals at high risk for developing cancer. For instance, according to Cancer Research UK, a UK-based cancer research organization, between 2023 and 2025, there’s an anticipated increase in new kidney cancer cases, rising from about 16,300 to roughly 21,900 by 2038–2040, i.e., a 15% increase within this period. Therefore, the high cancer prevalence is driving the growth of the clinical biomarker market.
Access Your Free Sample of the Global Clinical Biomarkers Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12670&type=smp
How does the future projection of the clinical biomarkers market size compare to its historical growth?
The clinical biomarkers market size has grown strongly in recent years. It will grow from $30.78 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increased prevalence of chronic disease, focus on personalized medicine and targeted therapies, drug development and clinical trials, regulatory support and funding
The clinical biomarkers market size is expected to see rapid growth in the next few years. It will grow to $52.8 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to expansion of companion diagnostics, focus on early diagnosis and disease prevention, increasing applications in precision oncology and neurodegenerative diseases, growing infectious diseases. Major trends in the forecast period include ai-powered biomarker discovery, machine learning integration, multi-omics integration, technological innovations, key players’ partnerships.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12670&type=smp
Which key players are shaping the future of the clinical biomarkers market?
Major companies operating in the clinical biomarkers market include Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., Epigenomics AG, Grifols S.A., Illumina Inc., BioMerieux SA., Charles River Laboratories International Inc., PerkinElmer Inc., Sartorius AG, Sysmex Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Luminex Corporation, Veracyte Inc., Centogene N.V., NanoString Technologies Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Siemens Healthcare Private Limited.
What trends will propel the growth and evolution of the clinical biomarkers market?
Technological advancements are a key trend gaining popularity in the clinical biomarker market. Major companies operating in the clinical biomarker market are developing innovative technologies to sustain their position in the market. For instance, in June 2023, Veravas Inc., a US-based manufacturer of medicinal products for enhancing laboratory medicine, launched VeraBIND (Biomarker Isolation and N-enrichment for Detection) technology. It provides a uniquely innovative and comprehensive approach that enhances the precision of biomarker identification and reduces the likelihood of false positive or negative results across a range of sample types. Clinical laboratories can improve their diagnostic procedures and aid in early disease detection by putting this invention into practice, allowing for prompt and focused interventions. Additionally, VeraBIND paves the path for quicker assay creation, providing precision and consistency in studies, clinical studies, and diagnostic screenings.
Which regions are expected to become dominant players in the clinical biomarkers market?
North America was the largest region in the clinical biomakers market in 2024. The regions covered in the clinical biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
What are the emerging key segments in the clinical biomarkers market, and how are they evolving?
The clinical biomarkers market covered in this report is segmented –
1) By Offering: Product, Service
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), Other Technologies
3) By Clinical Area: Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Immunological Biomarker, Non-Invasive Prenatal Testing, Other Clinical Areas
4) By Application: Clinical Diagnostic, Translational Research
5) By End User: Contract Research Organizations (CROs), Research And Academic Laboratories, Biopharmaceutical And Biotech Companies, Diagnostic Centers, Other End Users
Subsegments:
1) By Product: Diagnostic Kits, Reagents, Assay Kits, Instruments
2) By Service: Biomarker Discovery Services, Analytical Services, Clinical Trial Services, Data Analysis Services
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12670
What defines the structure and scope of the clinical biomarkers market?
Clinical biomarkers refer to quantifiable biological traits identifying normal or diseased bodily functions, such as chemicals or physiological indices. Clinical biomarkers help enhance patient care and personalized medicine by offering valuable data about a person’s health condition, disease progression, and prospective therapeutic targets.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
